A complex with nervous system modulating effects based on SMARTO-ONE technology

Abstract

The present invention relates to the field of biochemistry, and specifically provides a complex with a nervous system regulating effect based on SMARTO-ONE technology. The complex of the present invention includes two homemade components, kaempferol, dihydroquercetin, rutin and quercetin. The complex with a nervous system regulating effect based on SMARTO-ONE technology of the present invention adopts a variety of small molecule ketone complexes, which can achieve better nervous system regulation effects, and through the regulation of hormones in the body, the nervous system can be better repaired. It is mainly composed of a complex of dihydromyricetin, dihydroquercetin, rutin and kaempferol, which can be used to effectively regulate the nervous system of an organism and repair damaged nerves.

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a complex having a nervous system regulating effect based on SMARTO-ONE technology. Background Art

[0002] SMARTO-ONE is a food-grade brain neuronutrient dietary supplement first proposed, developed and promoted by a professor at the School of Pharmacy of the University of Southern California. It is used to replenish brain energy, help with quality sleep, and awaken brain nerve vitality. The main ingredients of SMARTO ONE are natural plant extracts such as Agave ulmoides leaves, Hovenia dulcis, Ebony plum, and cranberry. Its corresponding chemical components are small molecule flavonoid compounds, and its core components are mainly dihydromyricetin and its complexes. Therefore, in many studies, the neurological drug development technology based on small molecule flavonoids is called SMARTO-ONE technology.

[0003] Dihydroquercetin is a natural substance extracted from Siberian larch and Daurian larch. It is a dihydroflavonol compound belonging to the vitamin P family and is a widely used bioactive agent. Dihydroquercetin has multiple biological activities in the human body, including free radical scavenging, anti-oxidation, anti-inflammatory, vasodilation and antibacterial effects.

[0004] Dihydromyricetin (DHM) is a natural flavonoid compound extracted from Hovenia dulcis and Thunbergia paniculata. Scientific research has confirmed that dihydromyricetin can be used to treat neuropsychiatric diseases such as Alzheimer's disease and Parkinson's disease, as well as insomnia and mood disorders.

[0005] In the process of research and development based on SMARTO-ONE technology, how to promote the absorption and utilization of small molecule flavonoids has always been a focus of research and development. However, there have been few reports on the directional effects of small molecule flavonoids in the human brain. Summary of the invention

[0006] Since flavonoids are highly chemically reactive and antioxidant, they can be used to remove free radicals in the body and have therapeutic value for many human diseases. In addition, flavonoids can inhibit enzyme activity, have anti-cancer, anti-bacterial, anti-viral, and anti-inflammatory effects, so flavonoids have various reaction pathways in the human body. When they are used to treat specific diseases, it is often difficult for the efficacy to be concentrated in a specific area.

[0007] Since the applicant is mainly committed to the research and development of products for regulating the nervous system, and dihydromyricetin is a small molecule ketone that has been proven to have good nerve repair and regulation effects, but dihydromyricetin itself has poor water solubility, and there is huge room for improvement in its absorption and utilization effect. Therefore, the applicant tried to use dihydromyricetin to prepare various complexes, and used the complexes to conduct animal experiments to observe their effects on modifying the nervous system.

[0008] The inventors found in the test of the complex that dihydromyricetin combined with three-carbon substances can increase the secretion of neuron-specific enolase (NSE) after being taken by animals. Neuron-specific enolase is a specific enzyme present in the brains of humans and various animals. NSE is mainly present in nerve tissue and neuroendocrine tissue. The content of this enzyme can also be used to assist in the diagnosis of neuroblastoma. The fact that NSE can be used to detect brain diseases does not mean that it is the cause of brain diseases. NSE can indicate that brain cells have been damaged and acts similarly to white blood cells in the human body. It has the function of protecting and nourishing nerves in normal animal brain tissue.

[0009] NSE is one of the enolases involved in the glycolysis pathway. The inventors noticed in animal experiments that when the homemade components enter the animal's body for a period of time, the content of NSE will increase, and the effect of animal brain nerve repair will also increase. After taking it, the amount of NSE will return to normal levels and the animal's cognitive repair level will remain relatively good. However, homemade components cannot be used in excess. Excessive use will lead to excessive secretion of NSE, causing unknown risks. Therefore, the present invention uses it in combination with kaempferol, dihydroquercetin, rutin and quercetin.

[0010] Specifically, the present invention provides a complex with a nervous system regulating effect based on SMARTO-ONE technology, wherein the complex comprises a self-made component, kaempferol, dihydroquercetin, rutin and quercetin, wherein the self-made component accounts for 25-45% of the total mass of the complex, the total mass of dihydroquercetin, kaempferol and quercetin accounts for 35-45% of the total mass of the complex, and rutin accounts for 20%-40% of the total mass of the complex, wherein,

[0011] Homemade components were prepared as follows:

[0012] Step 2.1, take 20 mmol of dihydromyricetin, add it to 50 ml of anhydrous ethanol solution, and add it to the reactor;

[0013] Step 2.2, introducing helium or argon into the reaction kettle, and adding molecular sieve-attached palladium catalyst into the reaction kettle;

[0014] Step 2.3, add an excess of 2,3-dihydroxypropionic acid C3H6O4 to the reactor, add a small amount of dilute hydrochloric acid, adjust the pH value to less than 3.5 and greater than 2, and seal the reactor;

[0015] Step 2.4, the reactor is rapidly pressurized to above 3 MPa, and at the same time, the reactor is rapidly heated to above 90 degrees Celsius, hydrogen is introduced as a reducing agent, and the reaction is stirred at a constant temperature for 1-2 hours;

[0016] Step 2.5, cooling and reducing the pressure, filtering out the catalyst, removing the solvent and unreacted 2,3-dihydroxypropionic acid by low-temperature distillation, and drying to obtain a reaction product, i.e., a homemade component.

[0017] Preferably, the mass ratio of dihydroquercetin, kaempferol and quercetin is 1:1:0.6 to 1:1:1. The complex further comprises ampelopsis, and the mass ratio of ampelopsis to the total mass of the remaining raw materials is 1%-5%.

[0018] Preferably, the complex further comprises vitamin C.

[0019] Preferably, the complex further comprises cyclodextrin.

[0020] The present invention also provides a method for preparing a complex having a nervous system regulating effect based on the SMARTO-ONE technology, the method comprising:

[0021] The method comprises:

[0022] Step (1), preparing dihydromyricetin, 2,3-dihydroxypropionic acid C3H6O4, kaempferol, dihydroquercetin, quercetin and rutin;

[0023] Step (2), preparing a homemade component using dihydromyricetin and 2,3-dihydroxypropionic acid C3H6O4;

[0024] Step (3), mixing the self-made component, kaempferol, dihydroquercetin, quercetin and rutin according to a set mass ratio, adding an auxiliary preparation, and stirring evenly, wherein the self-made component accounts for 25-45% of the total mass of the composite, the total mass of dihydroquercetin, kaempferol and quercetin accounts for 35-45% of the total mass of the composite, and rutin accounts for 20%-40% of the total mass of the composite;

[0025] The step (2) comprises:

[0026] Step 2.1, take 20 mmol of dihydromyricetin, add it to 50 ml of anhydrous ethanol solution, and add it to the reactor;

[0027] Step 2.2, introducing helium or argon into the reaction kettle, and adding molecular sieve-attached palladium catalyst into the reaction kettle;

[0028] Step 2.3, add an excess of 2,3-dihydroxypropionic acid C3H6O4 to the reactor, add a small amount of dilute hydrochloric acid, adjust the pH value to less than 3.5 and greater than 2, and seal the reactor;

[0029] Step 2.4, the reactor is rapidly pressurized to above 3 MPa, and at the same time, the reactor is rapidly heated to above 90 degrees Celsius, hydrogen is introduced as a reducing agent, and the reaction is stirred at a constant temperature for 1-2 hours;

[0030] Step 2.5, cooling and reducing the pressure, filtering out the catalyst, removing the solvent and unreacted 2,3-dihydroxypropionic acid by low-temperature distillation, and drying to obtain a reaction product, i.e., a homemade component.

[0031] Preferably, among the raw materials, the self-made component accounts for 25-45% of the total mass of the composite, the mass of dihydroquercetin, kaempferol and quercetin accounts for 35-45% of the total mass of the composite, and rutin accounts for 20%-40% of the total mass of the composite. Rutin is used as a total amount regulating substance of the composite. While ensuring the ratio of the first two substances, rutin is used as a remaining supplementary substance, and when additional reaction products are added, part of the amount of rutin can be replaced.

[0032] Preferably, the auxiliary preparation includes vitamin C and cyclodextrin, and the mass of the auxiliary preparation is not included in the total mass of the complex during the raw material configuration.

[0033] Preferably, step (3) further comprises adding ampelopsis thunbergii, wherein the mass ratio of ampelopsis thunbergii to the total mass of the remaining raw materials is 1%-5%.

[0034] The complex with the nervous system regulating effect based on the SMARTO-ONE technology of the present invention adopts the compounding effect of multiple small molecule ketones to achieve a better nervous system regulating effect.

[0035] Technical Effects

[0036] The complex with nervous system regulating effect based on SMARTO-ONE technology of the present invention adopts a complex of dihydromyricetin and several other small molecule ketones to cooperate with NSE to enhance the nervous system regulating effect while enhancing its effect on the brain. Animal experiments show that the homemade components have no toxic side effects on organisms and have good absorption and utilization efficiency in the body. In addition, the homemade components can promote the secretion of NSE on the one hand, and on the other hand, due to its interaction with NSE, it can enhance the effect of nerve damage repair.

[0037] Dihydroquercetin is a widely used bioactive agent, which has many benefits for the human body, such as free radical scavenging, anti-oxidation, anti-inflammation, vasodilation and antibacterial. In the present invention, this ingredient is added and used in combination with the homemade components to improve the utilization rate of dihydromyricetin.

[0038] In addition, the present invention uses dihydromyricetin, kaempferol, dihydroquercetin, quercetin and rutin in combination, which can scavenge free radicals and have a good repair effect on damaged nerve cells, which can be seen from the fact that NSE in mouse brain cells first increases and then decreases.

[0039] Preferably, the complex of the present invention is mixed with acidic auxiliary materials such as vitamin C, which not only improves its ability to maintain activity in the gastrointestinal tract, but also promotes its concentration in the cranial nerves and enhances its action ratio in the cranial nerves. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 is the molecular structural formula of kaempferol used in the composite of the present invention;

[0041] Figure 2 is the molecular structural formula of dihydroquercetin used in the complex of the present invention;

[0042] Figure 3 The figure is a schematic flow chart of the method for preparing the composite of the present invention. DETAILED DESCRIPTION Example 1

[0043] This embodiment provides a compound with a nervous system regulating effect based on SMARTO-ONE technology, wherein the compound comprises a self-made component, kaempferol (whose molecular structure is as follows Figure 1 As shown), dihydroquercetin (its molecular structure is as shown Figure 2 As shown), quercetin and rutin (quercetin and rutin are common commercial substances, and their molecular formulas are not provided here), wherein the self-made component accounts for 35% of the total mass of the complex, the mass of dihydroquercetin, kaempferol and quercetin accounts for 37% of the total mass of the complex, and rutin accounts for 28% of the total mass of the complex. The present invention uses self-made components, kaempferol, dihydroquercetin, quercetin and rutin to prepare a complex, and through the complex action of several small molecule ketones, the regulation effect of the nervous system is enhanced while enhancing its effect on the brain.

[0044] like Figure 3 As shown, the preparation method of the composite of the present invention is as follows:

[0045] Step (1), prepare dihydromyricetin (C 15 H 12O8 CAS: 27200-12-0), 2,3-dihydroxypropionic acid C3H6O4 (CAS: 473-81-4), kaempferol (CAS: 520-18-3), dihydroquercetin (CAS: 480-18-2), quercetin (CAS: 117-39-5) and rutin (CAS: 153-18-4). Preferably, during production, the above raw materials are selected from natural material extracts as much as possible.

[0046] Step (2), using dihydromyricetin and 2,3-dihydroxypropionic acid to prepare a homemade component.

[0047] The step (2) specifically includes:

[0048] Step 2.1, take 20 mmol of dihydromyricetin, add it to 70 ml of anhydrous ethanol solution, and add it to the reactor.

[0049] Step 2.2, introducing helium or argon into the reactor, and adding a palladium-containing catalyst into the reactor, preferably, a palladium catalyst attached to a ZSM5 molecular sieve.

[0050] In a preferred implementation, the molecular sieve uses high silicon ZSM-5 molecular sieve, and the metal palladium uses 3-6nm palladium nanoparticles. The attachment process is: prepare a 3-5% palladium nitrate aqueous solution, place it in a water bath, stir and add polyvinyl alcohol, quickly stir and add NaBH4 and ZSM-5 molecular sieve, continue stirring for 3-4 hours, wash and dry, and calcine in a protective gas environment for 2 hours to remove residual organic matter to obtain a molecular sieve catalyst loaded with palladium nanoparticles.

[0051] Step 2.3, this step and step 2.4 are the preparation reaction process. In the operation, firstly, an excess of 2,3-dihydroxypropionic acid C3H6O4 is added to the reactor, and a small amount of dilute hydrochloric acid is added to adjust the pH value to less than 3.5 and greater than 2. The pH value should not be too high or too low, otherwise it will induce an esterification reaction. Preferably, 30-40 mmol of 2,3-dihydroxypropionic acid C3H6O4 is added, and the reactor is closed;

[0052] Step 2.4, quickly pressurize the reactor to 3-5 MPa. At the same time, quickly heat the reactor to above 90 degrees Celsius, introduce hydrogen as a reducing agent, and stir the reaction at a constant temperature for 1-2 hours to open the CO bond in 2,3-dihydroxypropionic acid and bind it to the carbon ring of dihydromyricetin.

[0053] A key to the reaction is rapid pressurization and rapid temperature increase, and another key is pH adjustment. Under acidic conditions, with rapid pressure and temperature increase operations, 2,3-dihydroxypropionic acid C3H6O4 and dihydromyricetin can achieve the opening and polymerization of the CO bond in 2,3-dihydroxypropionic acid. However, under neutral or alkaline conditions, 2,3-dihydroxypropionic acid and dihydromyricetin are prone to side reactions, reducing the reaction yield or even reaction failure.

[0054] Step 2.5, reduce the pressure and temperature, filter out the molecular sieve, and remove the solvent and unreacted 2,3-dihydroxypropionic acid by low-temperature distillation to obtain the reaction product after condensation. The self-made component is about 7.3g, and the reaction formula is as follows: Figure 1 Repeat steps 2.1-2.5 to prepare a sufficient amount of homemade components. A small amount of residual Cl ions can be filtered out by washing and drying using the difference in solubility.

[0055] The molecular weight of the product was determined by liquid phase mass spectrometry, and there was an obvious mass peak near 408, which matched its molecular weight. The aldehyde group was detected by Fehling's reagent, and the result was positive.

[0056] Step (3), accurately weigh 3.5 g of the homemade component, 1 g of dihydroquercetin, 1 g of kaempferol, 0.7 g of quercetin, and 2.8 g of rutin. Evenly mix the homemade component, kaempferol, dihydroquercetin, quercetin, and rutin, add 2 g of vitamin C and 3 g of cyclodextrin, and stir evenly. The evenly stirred complex is used for subsequent experiments.

[0057] It should be noted that when discussing the proportions of various raw materials in the present invention, the weight of the auxiliary preparation is not included (or the weight ratio of replacing part of rutin with the auxiliary preparation), and the weight ratio of the auxiliary preparation is relative to the total weight of all raw materials (self-made components, kaempferol, dihydroquercetin, rutin and quercetin).

[0058] Example 2

[0059] The composite in this embodiment includes homemade components, kaempferol, dihydroquercetin, quercetin and rutin, wherein the homemade components account for 42% of the total mass of the composite, the total mass of dihydroquercetin, kaempferol and quercetin accounts for 33% of the total mass of the composite, and rutin accounts for 25% of the total mass of the composite.

[0060] The preparation method of the composite of this embodiment is as follows:

[0061] Step (1), preparing dihydromyricetin, 2,3-dihydroxypropionic acid, kaempferol, dihydroquercetin, quercetin and rutin.

[0062] Step (2), using dihydromyricetin and 2,3-dihydroxypropionic acid to prepare a homemade component.

[0063] The step (2) specifically includes:

[0064] Step 2.1, take 20 mmol of dihydromyricetin, add it to 50 ml of anhydrous ethanol solution, and add it to the reactor.

[0065] Step 2.2, introducing helium or argon into the reactor, and adding a palladium-containing catalyst into the reactor, preferably, a palladium catalyst attached to a ZSM5 molecular sieve.

[0066] Step 2.3, add excess 2,3-dihydroxypropionic acid to the reactor, and adjust the pH value to less than 3.5. Preferably, add 30-40 mmol 2,3-dihydroxypropionic acid C3H6O4, and seal the reactor;

[0067] Step 2.4, quickly pressurize the reactor to 3.6 MPa. At the same time, quickly heat the reactor to above 90 degrees Celsius, stir and react at a constant temperature for 30 minutes, introduce hydrogen as a reducing agent, and continue stirring and reacting for 1-2 hours.

[0068] Step 2.5: First reduce the temperature and then reduce the pressure, and remove the solvent and unreacted 2,3-dihydroxypropionic acid by low-temperature distillation to obtain a condensed reaction product, about 6.9 g of the self-made component. Repeat this step to prepare a sufficient amount of the self-made component.

[0069] Step (3), accurately take 4.2g of the homemade component, 1.1g of dihydroquercetin, 1.1g of kaempferol, 1.1g of quercetin, and 2.5g of rutin. Evenly mix the homemade component, kaempferol, dihydroquercetin, quercetin, and rutin, add 2g of vitamin C and 3g of cyclodextrin, and stir evenly. The evenly stirred complex is used for subsequent experiments.

[0070] Example 3

[0071] In this example, the same raw material ratio as in Example 1 is used, except that the reaction conditions in steps 2.3 and 2.4 are different from those in Example 1.

[0072] In this embodiment, the preparation process of the product includes:

[0073] Step (1), preparing dihydromyricetin, 2,3-dihydroxypropionic acid, kaempferol, dihydroquercetin, quercetin and rutin.

[0074] Step (2), using dihydromyricetin and 2,3-dihydroxypropionic acid to prepare a homemade component.

[0075] Step 2.1, take 20 mmol of dihydromyricetin, add it to 70 ml of anhydrous ethanol solution, and add it to the reactor;

[0076] Step 2.2, introducing helium or argon into the reaction kettle, and adding a palladium-containing catalyst into the reaction kettle;

[0077] Step 2.3, adding an excess of 2,3-dihydroxypropionic acid into the reaction kettle;

[0078] Step 2.4: Heat the reactor to above 90 degrees Celsius and stir the reaction at constant temperature for 2 hours.

[0079] Step 2.5, remove the solvent and unreacted 2,3-dihydroxypropionic acid by low-temperature distillation to obtain about 4.5 g of homemade components. Compared with Example 1, in this example, the yield of the homemade components is reduced by nearly 40%, proving that pressurization has a significant promoting effect on the preparation.

[0080] Example 4

[0081] In this embodiment, the preparation method substantially the same as that in embodiment 1 is adopted, except that in this embodiment, the homemade component is replaced with dihydromyricetin, and the molar numbers of the two are the same.

[0082] The steps of this embodiment include:

[0083] Step (1), preparing dihydromyricetin, 2,3-dihydroxypropionic acid, kaempferol, dihydroquercetin, quercetin and rutin.

[0084] Step (2), accurately take 0.35g of dihydromyricetin (molecular weight 320.25), 0.1g of dihydroquercetin, 0.1g of kaempferol, 0.07g of quercetin, and 0.28g of rutin. Evenly mix the homemade components, kaempferol, dihydroquercetin, quercetin, and rutin, add 0.2g of vitamin C and 0.3g of cyclodextrin, and stir evenly. Weigh 0.5g of the mixed compound after stirring evenly and press it into tablets.

[0085] Animal experiments

[0086] In order to verify the effect of the complex based on SMARTO-ONE technology of the present invention on the regulation of the nervous system, the inventors conducted animal experiments using the complex in mice.

[0087] Neuron-specific enolase NSE has similar effects in mice, rats, rabbits, sheep, pigs, guinea pigs and other animals. Taking into account factors such as cost and cycle, the inventors used mice as experimental subjects.

[0088] Animal Experiment 1

[0089] 80 mice aged 15-20 months were taken and divided into four groups, each with 20 mice. The first group was the control group, the second group and the third group were fed with the complexes in Example 1 and Example 2, respectively, as Experimental Group 1 and Experimental Group 2, and the fourth group was fed with the complex in Example 4, as Experimental Group 3. Before the experiment, tetrodotoxin (TTX), a sodium channel blocker, was added to the food of the four groups of mice at a concentration of no more than 1 μM per mouse to damage the nervous system of the mice.

[0090] Starting from the next day, 1 mg / day of the therapeutic agent was added to the food of the mice in the three experimental groups. The control group selected 0.4 mg of vitamin C and 0.6 mg of cyclodextrin as substitutes. The first experimental group selected 1 mg of the complex prepared in Example 1, the second experimental group selected 1 mg of the complex prepared in Example 2, and the third experimental group selected 1 mg of the complex prepared in Example 4.

[0091] After 3 weeks, the cognitive tests were performed on the four groups of animals. The process is briefly described as follows:

[0092] Novel object recognition (NOR): Day 1-3: Habituation (once a day).

[0093] The mice were placed in an open-top container and used with a video camera to record the mouse behavior. The background was identical for each mouse.

[0094] Day 4: Familiarization.

[0095] Two identical objects (FO: familiar objects, here mazes or toys) were placed in a specific location of the mouse cage. The mouse was then placed in the container to explore the objects for 5 minutes. Each mouse was placed back in its home place for 1.5 hours after familiarization, and the process was repeated 3 times.

[0096] Day 5: Testing.

[0097] Place an object familiar to the mouse in a transparent container, place the mouse in a cage and test for 3 minutes, then place another new object NO in the cage. Then place the mouse in a cage and test for 3 minutes. The behavior of the mouse is scored offline based on how long the mouse explores each object. Calculate the object recognition index = tn / (tn + tf), where tf represents the time to explore the original object, and tn represents the time to explore the new object. The recognition index can also be expressed as (tn -tf) / (tn +tf).

[0098] The ORI value of each group was calculated based on the above formula.

[0099] The experimental results showed that the control group mice showed signs of reduced cognitive memory. After three weeks, the untreated control group mice spent more time exploring new objects (ORI = 82.5 ± 3.4%). In the mice in Experiment 1, the ORI decreased to 64.7 ± 2.8%, and the ORI in the mice in Experiment 2 decreased to 49.3 ± 3.4%. The ORI in the mice in Experiment 3 decreased to 59.5 ± 3.5%. Therefore, it can be shown that the cognitive ability of mice taking the complex of the present invention has been improved, and the cognitive ability of mice taking dihydromyricetin itself has been improved, and the nervous system repair is better.

[0100] Animal experiment 2

[0101] In order to verify the promoting effect of the homemade components on the secretion of neuron-specific enolase NSE, the inventors conducted quantitative tests on the content of neuron-specific enolase NSE in mouse brain cells and the content of NSE in blood in the control group, experimental group 1, experimental group 2 and experimental group 3 in animal experiment 1.

[0102] Specifically, the inventors took 10 mice that were not fed with neurotoxins as two control groups for brain nerve cell slices and serum sample extraction. 50% of the mice in the four experimental groups were subjected to brain cell slice extraction and serum sample extraction 3 weeks after feeding the drug. After 2 weeks after drug withdrawal, the other 50% of the mice were subjected to brain cell slice extraction and serum sample extraction. The soluble protein in the mouse brain cell samples was extracted and quantitatively tested using a neuron-specific enolase kit to test its proportion in the soluble protein. At the same time, blood samples were drawn to quantitatively test the content of NSE in the serum. The test results are as follows:

[0103] Test Group The proportion of NSE in soluble proteins in brain cells at 3 weeks Serum NSE level at 3 weeks (μg / L) The proportion of NSE content in soluble proteins in blood and brain cells at 5 weeks Serum NSE level at 5 weeks (μg / L) Control group 2.35%±0.02 25.3 2.42±0.02 23.6 Control group 2 1.83%±0.03 18.4 1.92±0.04 18.8 Experimental Group 1 3.47%±0.04 33.9 2.61±0.03 21.1 Experimental Group 2 3.65%±0.02 31.5 2.87±0.02 19.4 Experimental Group 3 2.13±0.03 23.2 2.12±0.04 20.8

[0104] Through comparison, it was found that after three weeks, the NSE content in brain cells of Experimental Group 1 and Group 2 increased significantly, and the content in serum increased slightly, indicating that the drugs in Experimental Group 1 and Group 2 can promote the secretion and concentration of NSE in brain cells, while the control group and Experimental Group 3 had increased NSE content in serum and brain cells due to nerve damage caused by toxins, but the increase was limited.

[0105] At five weeks, the proportion of NSE in soluble proteins in brain cells of Experimental Groups 1 and 2 decreased, and the content of NSE in serum basically returned to normal levels, proving that nerve damage was generally recovered, which can also be seen from the cognitive tests of mice. The brain damage in the control group was only slightly recovered, and the situation in Experimental Group 3 was better than that in the control group, but NSE did not concentrate in brain cells, proving that dihydromyricetin itself cannot promote the secretion and concentration of NSE. The complex of the present invention can promote the secretion of neuron-specific enolase NSE in mouse brain cells, and neuron-specific enolase NSE interacts with the homemade components, so that dihydromyricetin plays a role in brain cells, which is beneficial to the overall effect of the complex.

[0106] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Other modifications or equivalent substitutions made to the technical solution of the present invention by ordinary technicians in the field should be included in the scope of the claims of the present invention as long as they do not depart from the spirit and scope of the technical solution of the present invention.

Claims

1. A complex with nervous system regulation effect based on SMARTO-ONE technology, characterized in that: The composite comprises a self-made component, kaempferol, dihydroquercetin, rutin and quercetin, wherein the self-made component accounts for 42% of the total mass of the composite, the total mass of dihydroquercetin, kaempferol and quercetin accounts for 33% of the total mass of the composite, and rutin accounts for 25% of the total mass of the composite. The composite is prepared as follows: Step (1), preparing dihydromyricetin, 2,3-dihydroxypropionic acid, kaempferol, dihydroquercetin, quercetin and rutin; Step (2), the homemade components are prepared in the following manner: Step 2.1, take 20 mmol of dihydromyricetin, add it to 50 ml of anhydrous ethanol solution, and add it to the reactor; Step 2.2, introducing helium or argon into the reaction kettle, and adding molecular sieve-attached palladium catalyst into the reaction kettle; Step 2.3, add an excess of 2,3-dihydroxypropionic acid C3H6O4 to the reactor, add a small amount of dilute hydrochloric acid, adjust the pH value to less than 3.5 and greater than 2, and seal the reactor; Step 2.4, the reactor is rapidly pressurized to above 3.6 MPa, and at the same time, the reactor is rapidly heated to above 90 degrees Celsius, and the reaction is stirred at a constant temperature for 30 minutes, and hydrogen is introduced as a reducing agent, and the reaction is stirred at a constant temperature for 1-2 hours; Step 2.5, cooling and reducing the pressure, filtering out the catalyst, removing the solvent and unreacted 2,3-dihydroxypropionic acid by low-temperature distillation, and drying to obtain a reaction product; Wherein, the molecular sieve described in step 2.2 adopts high-silicon ZSM-5 molecular sieve, and the metal palladium adopts 3-6nm palladium nanoparticles; the attachment process is: prepare a 3-5% palladium nitrate aqueous solution, place it in a water bath, stir and add polyvinyl alcohol, quickly stir and add NaBH4 and ZSM-5 molecular sieve, continue stirring for 3-4h, wash and dry, and calcine in a protective gas environment for 2 hours to remove residual organic matter, and obtain a molecular sieve catalyst loaded with palladium nanoparticles; Step (3), accurately taking 4.2 g of the homemade component, 1.1 g of dihydroquercetin, 1.1 g of kaempferol, 1.1 g of quercetin, and 2.5 g of rutin, respectively, mixing the homemade component, kaempferol, dihydroquercetin, quercetin and rutin according to the set mass ratio, adding 2 g of vitamin C and 3 g of cyclodextrin. When the raw materials are configured, the mass of the auxiliary preparation is not included in the total mass of the complex.

2. A method for preparing a complex having a nervous system regulating effect based on SMARTO-ONE technology, characterized in that: The method comprises: Step (1), preparing dihydromyricetin, 2,3-dihydroxypropionic acid C3H6O4, kaempferol, dihydroquercetin, quercetin and rutin; Step (2), preparing a homemade component using dihydromyricetin and 2,3-dihydroxypropionic acid C3H6O4; Step (3), accurately taking 4.2 g of the homemade component, 1.1 g of dihydroquercetin, 1.1 g of kaempferol, 1.1 g of quercetin, and 2.5 g of rutin, respectively, mixing the homemade component, kaempferol, dihydroquercetin, quercetin, and rutin according to the set mass ratio, adding 2 g of vitamin C and 3 g of cyclodextrin. When the raw materials are prepared, the mass of the auxiliary preparation is not included in the total mass of the complex; The step (2) comprises: Step 2.1, take 20 mmol of dihydromyricetin, add it to 50 ml of anhydrous ethanol solution, and add it to the reactor; Step 2.2, introducing helium or argon into the reaction kettle, and adding molecular sieve-attached palladium catalyst into the reaction kettle; Step 2.3, add an excess of 2,3-dihydroxypropionic acid C3H6O4 to the reactor, add a small amount of dilute hydrochloric acid, adjust the pH value to less than 3.5 and greater than 2, and seal the reactor; Step 2.4, the reactor is rapidly pressurized to above 3.6 MPa, and at the same time, the reactor is rapidly heated to above 90 degrees Celsius, and the reaction is stirred at a constant temperature for 30 minutes, and hydrogen is introduced as a reducing agent, and the reaction is stirred at a constant temperature for 1-2 hours; Step 2.5, cooling and reducing the pressure, filtering out the catalyst, removing the solvent and unreacted 2,3-dihydroxypropionic acid by low-temperature distillation, and drying to obtain a reaction product; Wherein, the molecular sieve described in step 2.2 adopts high-silicon ZSM-5 molecular sieve, and the metal palladium adopts 3-6nm palladium nanoparticles; the attachment process is: prepare a 3-5% palladium nitrate aqueous solution, place it in a water bath, stir and add polyvinyl alcohol, quickly stir and add NaBH4 and ZSM-5 molecular sieve, continue stirring for 3-4h, wash and dry, calcine in a protective gas environment for 2 hours to remove residual organic matter, and obtain a molecular sieve catalyst loaded with palladium nanoparticles.

Images